Therefore, managing inflammation is always a relevant focus for therapy, and targeting TNF-α, IL-6, IL-8, and IL-1β remains a critical therapeutic strategy in managing RA and OA [25,26,27]. This evidence concerns the gene CXCL8 and rheumatoid arthritis.